Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer

Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have published pre-clinical data demonstrating the effectiveness of NEO-201 in Ovarian Cancer models. NEO-201 is currently being tested in a clinical trial at the NCI for patients with metastatic colorectal, pancreatic, NSCLC, breast and ovarian cancers.